While RAPT Therapeutics Inc has underperformed by -5.48%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RAPT rose by 119.86%, with highs and lows ranging from $42.39 to $5.67, whereas the simple moving average jumped by 110.03% in the last 200 days.
On October 27, 2025, Guggenheim started tracking RAPT Therapeutics Inc (NASDAQ: RAPT) recommending Buy. A report published by JP Morgan on October 20, 2025, Upgraded its rating to ‘Overweight’ for RAPT. Barclays also rated RAPT shares as ‘Overweight’, setting a target price of $35 on the company’s shares in an initiating report dated October 13, 2025. JP Morgan July 30, 2025d its ‘Underweight’ rating to ‘Neutral’ for RAPT, as published in its report on July 30, 2025. H.C. Wainwright’s report from May 22, 2025 suggests a price prediction of $6 for RAPT shares, giving the stock a ‘Buy’ rating. H.C. Wainwright also rated the stock as ‘Buy’.
Analysis of RAPT Therapeutics Inc (RAPT)
RAPT Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -85.37% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 12.04, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and RAPT has an average volume of 379.20K. On a monthly basis, the volatility of the stock is set at 9.30%, whereas on a weekly basis, it is put at 5.29%, with a loss of -4.30% over the past seven days. Furthermore, long-term investors anticipate a median target price of $64.38, showing growth from the present price of $27.79, which can serve as yet another indication of whether RAPT is worth investing in or should be passed over.
How Do You Analyze RAPT Therapeutics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 66.36%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 26.28% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
